Duke University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Duke University sits in the top decile of US sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count).
Duke University: 1,725 sponsored US clinical trials, 187 recruiting.
Duke University sponsors 1,725 registered US clinical trials on ClinicalTrials.gov, 187 of them currently recruiting, and 1,244 completed. 175 of these trials are in Phase 3-4 (later-stage) and 311 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 15 trials.
Top-decile sponsor footprint
Duke University ranks in the top decile of sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,244 of 1,444 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,725 total, page 29 of 35
Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide
NCT00900757
Rheumatoid Arthritis Coping Enhancement
NCT04246827
Cerebrospinal Fluid (CSF) Pharmacokinetics of Antimicrobials in Children
NCT00991185
Exercise Dose-Response Effects in Prediabetes
NCT00962962
Study of Intracranial Pressure (ICP) Monitoring in Critically Ill
NCT01330264
Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)
NCT00786474
Neuroimaging of Smokers With and Without Attention Deficit Hyperactivity Disorder (ADHD)
NCT01123668
Mindfulness, Emotional Well-being, and Sleep Quality
NCT00887614
Lidocaine For Neuroprotection During Cardiac Surgery
NCT00938964
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
NCT00887640
BraveNet Multi-Center Study on Integrative Medicine Treatment Approaches for Pain
NCT01186341
The Genetics of Chiari Type I Malformation
NCT01060800
Continuous Cardiac Arrhythmia Monitoring in Hemodialysis Patients
NCT00932659
Effect on Bleeding When Using FloSeal Matrix™ in Subjects Undergoing Endoscopic Vein Harvest (EVH)
NCT00742313
Atkins Diet and Prostate Cancer Clinical Trial
NCT00932672
Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype
NCT00894166
Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS
NCT00887679
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant
NCT00901225
Acceptance-Based Separated Family Treatment for Adolescent Anorexia Nervosa
NCT01274416
A Controlled Laboratory Study of the Effects on Cue-Induced Craving in Dependent Smokers
NCT00901459
Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer
NCT00918385
Infection Rates of Myeloablative Allo SCT Recipients Receiving Neutropenic Diets Versus Non-Neutropenic Diets
NCT01687231
Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)
NCT00889915
Effect of Type 2 Diabetes Genetic Risk Information on Health Behaviors and Outcomes
NCT00849563
p16 Methylation for Smoking Cessation
NCT01038492
Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)
NCT00736385
Alternate Dosing Schedules Study for HPV Vaccine (ADS)
NCT02280642
Coping Skills and Heart Failure: Outcomes and Mechanisms
NCT00873418
Neurobiology of Nicotine and Non-nicotine Components of Tobacco Addiction
NCT01056926
Validating PROMIS Instruments in Congestive Heart Failure Patients Receiving a Heart Transplant
NCT00783848
Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes
NCT00828802
Alternate Dosing Schedules Study for HPV Vaccine
NCT00862810
Ventriculostomy in Subarachnoid Hemorrhage (SAH): Intracranial Pressure (ICP) Open or Not?
NCT01169454
Targeted Feedback Reports to Improve Acute Coronary Syndromes (ACS) Care
NCT00952250
Validation of Brain Oxygenation Monitor on Pediatric Patients
NCT00849940
Extinction Based Treatment for Nicotine Dependence
NCT00831155
Post-traumatic Stress Disorder (PTSD), Addiction, and Virtual Reality
NCT01186315
Erectile Dysfunction Study
NCT00873665
Prevention of Intraoperative Nausea and Vomiting During Cesarean Section
NCT01216410
Cholesterol, Hypertension and Glucose Education Study
NCT00815789
Multimodality Phase II Study in Prostate Cancer
NCT00734851
A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)
NCT00735436
Coping With High Grade Glioma
NCT00815152
Spinal Cord Stimulator Implant Study
NCT00887419
Impact of GBS on CVD in Type 2 Diabetes Mellitus
NCT00787670
Ventriculostomies in SAH: ICP Open or Not?
NCT00787020
Cognitive Effects of Inhalational Versus Intravenous General Anesthesia in the Elderly
NCT00788008
Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting
NCT00828555
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
NCT00744692
Escitalopram Treatment of Night Eating Syndrome
NCT00636649
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 136 |
| Phase 2 | 175 |
| Phase 3 | 41 |
| Phase 4 | 134 |
Therapeutic Areas
What is open in the Duke University pipeline
187 recruiting of 1,725 indexed (11% open); 1,244 completed (72%).
Phase mix: 175 late (III/IV) vs 311 early (I/II) (early-phase heavy).
Top condition: Obesity (15 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Duke University: open-pipeline peers nationwide
Peers matched on 1,725 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
Duke University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,725 trials (± recruiting share)
- University of California, San Francisco · 1,713 trials · 16% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- VA Office of Research and Development · 1,668 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
Sponsors near 11% open enrollment (± trial volume)
- Carnegie Mellon University · 11% recruiting · 37 trials
- CAMC Health System · 11% recruiting · 28 trials
- UConn Health · 11% recruiting · 178 trials
- Hartford Hospital · 11% recruiting · 75 trials
Related
What to do with this Duke University page
1,725 registered trials is a research-attention snapshot, not an endorsement of Duke University or any single study.
- 187 of Duke University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition Duke University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Duke University pipeline card: 1,725 registered trials from official public datasets.Report a data error.